Cramer Friday 2/17/2006 After Close
...
Finally, Cramer said he had to clarify his position on Pain Therapeutics (PTIE:Nasdaq). He bagged the company during a lighting round, which was an inconsistent call.
So he welcomed Remi Barbier, the CEO of Pain Therapeutics, to talk about the company's latest moves.
Pain Therapeutics is working on a painkiller that causes less physical dependency, as well as an abuse-resistant version of an existing drug, Barbier said.
The company has also partnered with King Pharma (KG:NYSE ) to make painkillers, the chief executive said.
Cramer asked if the stock is stagnant because it's not getting analyst coverage.
Barbier said that while that could be one reason, he reminded Cramer that it takes time for these stories to catch investor attention.
He added that Pain Therapeutics doesn't need to raise any more cash, because they have over $200 million of cash on the books and a very low burn rate.
-----
Lightning Round
Bullish - GENZ
Bearish - ELN
thestreet.com
_______________
Thursday 2/16/2006
...
"If you do the E.M. Forster thing and go to India," he said to take a look at Tata Motors (TTM:NYSE ADR ) and Dr. Reddy's Laboratories (RDY:NYSE ADR ) to get into both sectors.
The Indian market is exploding, a factor that makes both stocks look intriguing, he said.
As far as Dr. Reddy's in concerned, Cramer doesn't usually like generic-drug companies, but the said that the company is embarking on some growth acquisitions that could be "just what the doctor ordered."
Dr. Reddy's is doing an offering to pay for its latest acquisition, giving investors an opportunity to sneak in and buy.
But, he warned, "If you're buying [Dr. Reddy's] after hours, you have no concept of what you're doing whatsoever."
He also said that if Bristol-Myers (BMY:NYSE - news - research - Cramer's Take) loses its patent on Plavix, then this generic-drug play could benefit.
...
Cramer welcomed Patrick Sullivan, chairman and chief executive of Cytyc (CYTC:Nasdaq), a company that specialized in the women's health care sector.
Cytyc makes products to detect cervical and breast cancer, and Sullivan said they have a large share of the pap-test market.
He also said that the company's fourth-quarter revenue increased by 25%, and that its new products should generate continued growth.
One product he seemed particularly upbeat about is a new product that will treat abnormal uterine bleeding, for which he says there will be a large market.
[Interview Available Online] |
